Equity Profile

NVO

Novo Nordisk A/S

Health CarePharmaceuticals$188.3B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Novo Nordisk A/S is a global leader in the health care sector, specializing in diabetes care and hormone replacement therapies. With a market cap of $188 billion, the company plays a crucial role in addressing chronic health conditions, particularly as global diabetes rates continue to rise.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge its financial health this quarter.

N/A

Revenue Growth

Revenue growth is vital for assessing how well Novo Nordisk is expanding its market presence and product sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+37.68%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In the last quarter, Novo Nordisk reported an EPS of $1.04, exceeding expectations by 18.71%. The stock reacted positively, gaining 1.98% the following day.

Management Promises & Guidance

Focus on expanding diabetes care solutions.
Commitment to innovation in hormone therapies.
Plans to enhance global market penetration.

Expectations

Wall Street Expectations

Overall, expectations are mixed ahead of the earnings report, with investors looking for signs of continued growth in diabetes care.

Bull Case

If Novo Nordisk can demonstrate strong sales growth in its diabetes products and maintain or improve its EPS, it could lead to a significant upward revision in stock price.

Bear Case

Conversely, if the company reports disappointing sales figures or misses EPS expectations, it could trigger a sell-off, reflecting concerns about its growth trajectory.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the specific sales figures for diabetes products this quarter?

Sales performance in this segment is critical for understanding the company's growth and market position.

How does management view the competitive landscape for diabetes treatments?

Insights into competition will help investors gauge potential market challenges and opportunities.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Novo Nordisk's diabetes products to outperform due to increasing global demand and innovative treatments.

Supporting Evidence

Recent trends show rising diabetes rates, which could drive higher sales than expected.

The company's historical performance indicates resilience even in challenging market conditions.

Key Risk

If diabetes product sales exceed expectations significantly, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Novo Nordisk's ability to sustain its growth in a competitive market.

Bull Confirmed If

A strong increase in diabetes product sales, exceeding previous quarter figures, would confirm the bull case.

Bear Confirmed If

A decline in sales or a significant miss on EPS would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.26%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.3% while NVO has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.8%

Calls (2.8M)P/C Ratio: 0.57Puts (1.1M)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

9.45%

of float

Insider

0.01%

of float

Holders

1,641

institutions

Top Holders· as of Dec 2025

LOOMIS SAYLES & CO L P
17,135,384 sh · $705.5M
0.51%
6.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novo Nordisk beats expectations, history suggests a potential stock increase of around 3.59%, confirming confidence in its growth strategy.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience muted movement.

Miss

A miss could lead to a decline of approximately 4.09%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diabetes product launches.
2Management's commentary on market share changes.
3Details on R&D advancements in hormone therapies.
4Insights into cost management and operational efficiency.
5Guidance on future revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge its financial health this quarter.

N/A

Revenue Growth

Revenue growth is vital for assessing how well Novo Nordisk is expanding its market presence and product sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+37.68%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In the last quarter, Novo Nordisk reported an EPS of $1.04, exceeding expectations by 18.71%. The stock reacted positively, gaining 1.98% the following day.

Management Promises & Guidance

Focus on expanding diabetes care solutions.
Commitment to innovation in hormone therapies.
Plans to enhance global market penetration.

Expectations

Wall Street Expectations

Overall, expectations are mixed ahead of the earnings report, with investors looking for signs of continued growth in diabetes care.

Bull Case

If Novo Nordisk can demonstrate strong sales growth in its diabetes products and maintain or improve its EPS, it could lead to a significant upward revision in stock price.

Bear Case

Conversely, if the company reports disappointing sales figures or misses EPS expectations, it could trigger a sell-off, reflecting concerns about its growth trajectory.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the specific sales figures for diabetes products this quarter?

Sales performance in this segment is critical for understanding the company's growth and market position.

How does management view the competitive landscape for diabetes treatments?

Insights into competition will help investors gauge potential market challenges and opportunities.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Novo Nordisk's diabetes products to outperform due to increasing global demand and innovative treatments.

Supporting Evidence

Recent trends show rising diabetes rates, which could drive higher sales than expected.

The company's historical performance indicates resilience even in challenging market conditions.

Key Risk

If diabetes product sales exceed expectations significantly, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Novo Nordisk's ability to sustain its growth in a competitive market.

Bull Confirmed If

A strong increase in diabetes product sales, exceeding previous quarter figures, would confirm the bull case.

Bear Confirmed If

A decline in sales or a significant miss on EPS would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.26%

Historical Avg

±3.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±9.3% while NVO has averaged ±3.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

33.8%

Calls (2.8M)P/C Ratio: 0.57Puts (1.1M)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

9.45%

of float

Insider

0.01%

of float

Holders

1,641

institutions

Top Holders· as of Dec 2025

LOOMIS SAYLES & CO L P
17,135,384 sh · $705.5M
0.51%
6.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novo Nordisk beats expectations, history suggests a potential stock increase of around 3.59%, confirming confidence in its growth strategy.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience muted movement.

Miss

A miss could lead to a decline of approximately 4.09%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new diabetes product launches.
2Management's commentary on market share changes.
3Details on R&D advancements in hormone therapies.
4Insights into cost management and operational efficiency.
5Guidance on future revenue expectations.